Nonconvulsive Seizure Control in the Intensive Care Unit

Current Treatment Options in Neurology

Volumn 17, Issue 3, 2015, Pages 1-9

  Wasim, Mariam ^a   Husain, Aatif M ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Continuous EEG monitoring; Lacosamide; Levetiracetam; Nonconvulsive seizures; Nonconvulsive status epilepticus; Phenytoin; Pregabalin; Topiramate; Treatment; Valproic acid

Indexed keywords

ETIRACETAM; FOSPHENYTOIN SODIUM; HARKOSERIDE; PHENYTOIN; PREGABALIN; TOPIRAMATE; VALPROIC ACID;

ADVERSE DRUG REACTION; ANTICONVULSANT THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DRUG COST; DRUG EFFICACY; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONCONVULSIVE SEIZURE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; TREATMENT CONTRAINDICATION;

EID: 84922746249     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-015-0340-y     Document Type: Review

References (30)

1. Husain AM, Horn GJ, Jacobson MP. Non-convulsive status epilepticus: usefulness of clinical features in selecting patients for urgent EEG. J Neurol Neurosurg Psychiatry. 2003;74(2):189–91.
2. Claassen J, Mayer SA, Kowalski RG, et al. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology. 2004;62(10):1743–8.
3. Jette N, Claassen J, Emerson RG, Hirsch LJ. Frequency and predictors of nonconvulsive seizures during continuous electroencephalographic monitoring in critically ill children. Arch Neurol. 2006;63(12):1750–5.
4. Zehtabchi S, Abdel Baki SG, Malhotra S, et al. Nonconvulsive seizures in patients presenting with altered mental status: an evidence-based review. Epilepsy Behav. 2011;22(2):139–43.
5. Naeiji G, Depondt C, Meeus C, et al. EEG patterns compatible with nonconvulsive status epilepticus are common in elderly patients with delirium: a prospective study with continuous EEG monitoring. Epilepsy Behav. 2014;36:18–21.
6. Vespa PM, Miller C, McArthur D, et al. Nonconvulsive electrographic seizures after traumatic brain injury result in a delayed, prolonged increase in intracranial pressure and metabolic crisis. Crit Care Med. 2007;35(12):2830–6.
7. Claassen J, Albers D, Schmidt JM, et al. Nonconvulsive seizures in subarachnoid hemorrhage link inflammation and outcome. Ann Neurol. 2014;75(5):771–81.
8. Nicolai J, Ebus S, Biemans DP, et al. The cognitive effects of interictal epileptiform EEG discharges and short nonconvulsive epileptic seizures. Epilepsia. 2012;53(6):1051–9.
9. DeGiorgio CM, Heck CN, Rabinowicz AL, et al. Serum neuron-specific enolase in the major subtypes of status epilepticus. Neurology. 1999;52(4):746–9.
10. Vespa PM, Nuwer MR, Nenov V, et al. Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring. J Neurosurg. 1999;91(5):750–60.
11. Westover MB, Shafi MM, Bianchi MT, et al. The probability of seizures during EEG monitoring in critically ill adults. Clin Neurophysiol. 2014;pii:S1388-2457(14)00362-9. This study notes that most critically ill patients have abnormalities noted early in their cEEG studies.
12. Swisher CB, Shah D, Sinha SR, and Husain AM. Baseline EEG pattern on continuous ICU EEG monitoring and incidence of seizures. J Clin Neurophysiol. 2014. PMID: 25437330. This study discusses early EEG findings and their relationship to eventually developing seizures in critically ill patients.
13. Abend NS, Dlugos DJ, Hahn CD, et al. Use of EEG monitoring and management of non-convulsive seizures in critically ill patients: a survey of neurologists. Neurocrit Care. 2010;12(3):382–9.
14. Gavvala J, Abend N, LaRoche S, et al. Continuous EEG monitoring: a survey of neurophysiologist and neurointensivists. Epilepsia. 2014;55(11):1864–71.
15. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23. This paper analyzed available literature to establish evidence-based guidelines for acute treatment of SE in critically ill patients.
16. Litt B, Wityk RJ, Hertz SH, et al. Nonconvulsive status epilepticus in the critically ill elderly. Epilepsia. 1998;39(11):1194–202.
17. French JA, Gazzola DM. Antiepileptic drug treatment: new drugs and new strategies. Continuum (Minneap Minn). 2013;19(3):643–55. This article provides a concise overview of the mechanisms, toxicities and strategies for selection of old and new AEDs for treatment of various seizure types.
18. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998;339(12):792–8.
19. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure. 2014;23:167–74. This meta-analysis of studies evaluating the relative efficacy of five commonly used AEDs in benzodiazepine-resistant convulsive SE provides a great overview of the evidence that supports or does not support current practices.
20. Fischer JH, Patel TV, Fischer PA. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet. 2003;42(1):33–58.
21. Browne TR, Kugler AR, Eldon MA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology. 1996;46(6 Suppl 1):S3–7.
22. Boucher BA, Feler CA, Dean JC, et al. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. Pharmacotherapy. 1996;16(4):638–45.
23. Crandall A, Griffis MN, Holquist CA (2010) Intravenous phenytoin and fosphenytoin safety concerns background package. Joint Peripheral and Central Nervous System Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Meeting. November 3, 2010. U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER). This meeting highlighted the important side effects of PHT and fPHT and noted that fPHT is not as benign as originally thought especially given its cardiac side effects.
24. Trinka E, Hofler J, Zerbs A, et al. Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS Drugs. 2014;28:623–39. This systematic review highlights the safety and efficacy of IV VPA in patients who have failed initial conventional therapy for SE.
25. Rossetti AO, Bromfield EB. Determinants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav. 2006;8(3):651–4.
26. Swisher CB, Doreswamy M, Husain AM. Use of pregabalin for nonconvulsive seizures and nonconvulsive status epilepticus. Seizure. 2013;22(2):116–8.
27. Towne AR, Garnett LK, Waterhouse EJ, et al. The use of topiramate in refractory status epilepticus. Neurology. 2003;60(2):332–4.
28. Doreswamy M, Lassiter T, Husain AM. Use of lacosamide in nonconvulsive seizures in critically ill patients. Epilepsia 2010. Presented at the American Epilepsy Society annual meeting, 2010: http://www.aesnet.org/go/publications/aes-abstracts/abstract-search/mode/display/st/husain/sy/2010/sb/All/id/12788.
29. Hoffler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia. 2013;54(3):393–404. This paper reports the world-wide experience with lacosamide in NCS and NCSE.
30. Husain AM. Treatment of Recurrent Electrographic Nonconvulsive Seizures (TRENdS) Study. Epilepsia. 2013;54 Suppl 6:84–8. This paper describes the first randomized, multicenter clinical trial evaluating two AEDs in the treatment of NCS.